FANJ
BLPH

Financial Architects (New Jersey)’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Financial Architects (New Jersey)’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$3K – 848
2020
Q2 		$3K Buy
+200
New +$2.8K ﹤0.01% 794

Other funds holding BLPH

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Financial Architects (New Jersey)'s BLPH Position: Q3 2020 in Review

Financial Architects (New Jersey) sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2020, closing a stake of 200 shares — an estimated $3K sold.

Financial Architects (New Jersey) first reported a position in BLPH in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 41 funds tracked by Wall St. Rank hold BLPH as of Q3 2020.

  • Financial Architects (New Jersey) reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 200 Bellerophon Therapeutics, Inc. shares in Q3 2020, an estimated $3K.
  • Financial Architects (New Jersey) first reported a position in Bellerophon Therapeutics, Inc. in Q2 2020 and held it in 1 quarter.
  • Financial Architects (New Jersey)'s Bellerophon Therapeutics, Inc. position peaked at $3K in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2020.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2020, filed 9 Nov 2020.